Document Detail

Biochemical characterization of selective inhibitors of human group IIA secreted phospholipase A(2) and hyaluronic acid-linked inhibitor conjugates.
MedLine Citation:
PMID:  23020658     Owner:  NLM     Status:  MEDLINE    
We explored the inhibition mode of group IIA secreted phospholipase A(2) (GIIA sPLA(2)) selective inhibitors and tested their ability to inhibit GIIA sPLA(2) activity as chemical conjugates with hyaluronic acid (HA). Analogues of a benzo-fused indole sPLA(2) inhibitor were developed in which the carboxylate group on the inhibitor scaffold, which has been shown to coordinate to a Ca(2+) ligand in the enzyme active site, was replaced with other functionality. Replacing the carboxylate group with amine, amide, or hydroxyl groups had no effect on human GIIA (hGIIA) sPLA(2) inhibition potency but dramatically lowered inhibition potency against hGV and hGX sPLA(2)s. An alkylation protection assay was used to probe active site binding of carboxylate and noncarboxylate inhibitors in the presence and absence of Ca(2+) and/or lipid vesicles. We observed that carboxylate-containing inhibitors bind the hGIIA sPLA(2) active site with low nanomolar affinity, but only when Ca(2+) is present. Noncarboxylate, GIIA sPLA(2) selective inhibitors also bind the hGIIA sPLA(2) active site in the nanomolar range. However, binding for GIIA sPLA(2) selective inhibitors was dependent on the presence of a lipid membrane and not Ca(2+). These results indicate that GIIA sPLA(2) selective inhibitors exert their inhibitory effects by binding to the hGIIA sPLA(2) active site. An HA-linked GIIA inhibitor conjugate was developed using peptide coupling conditions and found to be less potent and selective against hGIIA sPLA(2) than the unconjugated inhibitor. Compounds reported in this study are some of the most potent and selective GIIA sPLA(2) active site binding inhibitors reported to date.
Rob C Oslund; Michael H Gelb
Related Documents :
23371498 - Nematicidal activity of three novel extracellular proteases of the nematophagous fungus...
24915748 - The kinetic analysis of the substrate specificity of motif 5 in a had hydrolase-type ph...
23545108 - Discovery of a novel series of non-nucleoside thumb pocket 2 hcv ns5b polymerase inhibi...
23976948 - Fast docking on graphics processing units via ray-casting.
20655568 - Michael acceptor properties of 6-bicycloaryl substituted (r)-5,6-dihydro-2h-pyran-2-ones.
3572968 - Structure-activity relationship in paf-acether. 3. hydrophobic contribution to agonisti...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2012-10-18
Journal Detail:
Title:  Biochemistry     Volume:  51     ISSN:  1520-4995     ISO Abbreviation:  Biochemistry     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2013-01-18     Completed Date:  2013-03-19     Revised Date:  2013-11-04    
Medline Journal Info:
Nlm Unique ID:  0370623     Medline TA:  Biochemistry     Country:  United States    
Other Details:
Languages:  eng     Pagination:  8617-26     Citation Subset:  IM    
Departments of Chemistry and Biomolecular Structure and Design, University of Washington, Seattle, WA 98195, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Catalytic Domain
Drug Design
Enzyme Inhibitors / chemistry*,  pharmacology*
Hyaluronic Acid / chemistry*,  pharmacology*
Inhibitory Concentration 50
Models, Molecular
Phospholipases A2 / antagonists & inhibitors*,  metabolism
Protein Binding
Grant Support
Reg. No./Substance:
0/Enzyme Inhibitors; 9004-61-9/Hyaluronic Acid; EC A2

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Circulation of West Nile virus lineage 1 and 2 during an outbreak in Italy.
Next Document:  Treatment of peri-implantitis using multiple applications of chlorhexidine chips: a double-blind, ra...